ClinicalTrials.gg
CompletedNCT02045017Updated Aug 27, 2021

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

A Phase 2 interventional study of Pomalidomide and Dexamethasone in Multiple Myeloma, sponsored by Celgene. Completed at 22 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-27.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 102 studies testing pomalidomide in Multiple Myeloma — 15 open to participants now, 39 under way, 9 of them phase 3. pomalidomide · Multiple Myeloma.

Enrollment
32nd of 102
81 · median 50
Started
2014
with 10 others
Phase 2
55 of 102
9 open now
Registered
27th of 102
by date
Lead sponsor
10 of 102
Celgene

Among the 102 studies testing pomalidomide in Multiple Myeloma, this one is the 32nd largest by enrollment, is one of 11 that started in 2014, is one of 55 in phase 2, and was the 27th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 102 studies testing pomalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About pomalidomide

pomalidomide: first FDA approval 2013 (POMALYST), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies testing pomalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary purpose of the study is to determine the safety and efficacy and to generate PK and biomarker data for the combination of Pomalidomide and low-dose Dexamethasone in patients with relapsed or refractory multiple myeloma, with moderate or severe renal impairment.

Read the detailed description

The study will consist of a Screening phase within 28 days prior to cycle 1 day 1. Subjects once enrolled will enter the Treatment phase, in which patients will be treated until progression, or study discontinuation due to other reasons. Subjects will enter the long term Follow-up phase of the study where data will be collected every 3 months for up to 5 years on Secondary primary malignancies, survival, subsequent anti myeloma treatments and date of progression. Subjects will be recruited into one of 3 cohorts depending on the severity of their renal impairment.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Refactory Multiple Myeloma
  • Renal Insufficiency
  • Pomalidomide
  • Dexamethasone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must satisfy the following criteria to be enrolled in the study.
  1. Subjects must have documented diagnosis of multiple myeloma and have (serum M-protein ≥ 0.5 g/dL or urine M-protein ≥ 200 mg/24 hours).
  1. Subjects must have had at least 1 prior antimyeloma regimen including lenalidomide and documented progression as per the International Myeloma Working Group uniform response criteria (Durie, 2006) during or after the last antimyeloma regimen. Induction therapy followed by Stem Cell Transplant and consolidation/ maintenance will be considered as one regimen.
  1. Subjects must have an impaired renal function with an estimated Glomerular Filtrate Rate of \< 45 mL/min/1.73 m2 according to the modification of diet in renal disease equation.
  1. Impaired renal function must be due to multiple myeloma which needs to be confirmed by kidney .
  2. Subjects may have acute myeloma related renal failure or chronic myeloma related renal failure; they may also have been treated with dialysis before, including dialysis with high cut off membranes.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment

  1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  3. Renal insufficiency due to other reasons than multiple myeloma or due to hypocalcaemia only.
  4. Prior history of , other than MM, unless the subject has been free of the disease for ≥ 5 years; exceptions include the following:

    1. Basal or squamous cell carcinoma of the skin
    2. Carcinoma in situ of the cervix or breast
    3. Incidental histological finding of prostate cancer (Tumour lymphNode stage of T1a or T1b)
  1. Previous therapy with pomalidomide. 7. to thalidomide, lenalidomide, or dexamethasone (this includes ≥ Grade 3 rash during prior thalidomide or lenalidomide therapy).
  1. Subjects who are planning for or who are eligible for stem cell transplant.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Pomalidomide and low dose Dexamethasone

    Pomalidomide 4mg, and low dose Dexamethasone, starting at 40mgs(≤ 75 years old) or 20 mg/day (\> 75 years old)

    Drug: Pomalidomide and Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate efficacy of the combination of pomalidomide and low-dose dexamethasone in subjects with RRMM and impaired renal function

    Overall response rate determined by Myeloma responses determined by modified IMWG criteria

    Time frame: Approximately 2 years

Secondary outcomes

  1. Assessment of renal response according to the criteria defined by Dimopoulos and Ludwig (Dimopoulos, 2009; Dimopoulos, 2010 b,c; Ludwig, 2010).

    Assessment of renal response according to the criteria defined by Ludwig and Dimopoulos

    Time frame: Approximately 2 years

  2. Time to Myeloma response

    Evaluated according to the CTCAE grading

    Time frame: Approximately 2 years

  3. Time to renal response

    Evaluated according to the CTCAE grading

    Time frame: Approximately 2 years

  4. Duration of response

    Evaluated according to the CTCAE grading

    Time frame: Approximately 2 years

  5. Progression-free survival

    Evaluated according to the CTCAE grading

    Time frame: Approximately 2 years

  6. Time to progression

    Evaluated according to the CTCAE grading

    Time frame: Approximately 2 years

  7. Overall Survival

    Evaluated according to the CTCAE grading

    Time frame: Approximately 2 years

  8. Adverse events (AEs) assessment (type, frequency, seriousness, severity, relationship to pomalidomide and/or dexamethasone and outcomes) including second primary malignancy (SPM).

    Pharmacokinetics (PK) of pomalidomide in subjects with RRMM and impaired renal function (moderate to severe renal impairment).

    Time frame: Approximately 2 years

07

Study locations

22 sites
  • Krankenhaus der Elisabethinen Linz, I Interne Abteilung
    Linz, 4020, Austria
  • Medizinische Universitat Wien
    Wien, 1090, Austria
  • Wilhelminenspital der Stadt Wien
    Wien, 1160, Austria
  • Hopital Dypuytren-CHU de Limoges
    Limoges cedex, 87042, France
  • Hopital Saint Louis
    Paris, 75475, France
  • CHU de Poitiers
    Poitiers, 86021, France
  • Medizinische Klinik und Poliklinik V Hamatologie, Onkologie und Rheumatologie
    Neuenheimer Feld 410, 69120, Germany
  • University Hospital Tubingen
    Tubingen, 72076, Germany
  • Alexandra Hospital, University of Athens
    Athens, 11528, Greece
  • Azienda Ospedaliero Universitaria Ospedali
    Ancona, 60126, Italy
  • S.C. Oncologia Medica
    Lecco, 23900, Italy
  • Ospedale Maggiore Policlinico Mangiagalli Regina Elena
    Milano, 20122, Italy
  • Arcispedale Santa Maria Nuova
    Reggio Emilia, 42100, Italy
  • VU University Medical Center VU Medisch Centrum
    Amsterdam, 1081 HV, Netherlands
  • Daniel den Hoed Kliniek Medical Oncology, Erasmus MC
    Rotterdam, 3075 EA, Netherlands
  • Hospital de La Princesa
    Madrid, 28006, Spain
  • CEIC Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario Doctor Peset
    Valencia, 46017, Spain
  • Queen Elizabeth Hospital UHB NHS Foundation Trust
    Birmingham, B15 2TH, United Kingdom
  • Ninewells Hospital and Medical School
    Dundee, DD1 9SY, United Kingdom
  • Oxford Radcliffe Hospital ICRF Medical Oncology Unit
    Headington, OX37LJ, United Kingdom
  • St Thomas' HospitalGuy's Hospital Dept. of Haematology
    London, SE1 9RT, United Kingdom
08

References and documents

Publications

  • Li Y, Wang X, O'Mara E, Dimopoulos MA, Sonneveld P, Weisel KC, Matous J, Siegel DS, Shah JJ, Kueenburg E, Sternas L, Cavanaugh C, Zaki M, Palmisano M, Zhou S. Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function. Clin Pharmacol. 2017 Nov 8;9:133-145. doi: 10.2147/CPAA.S144606. eCollection 2017. PubMed 29184451 ↗
  • Dimopoulos M, Weisel K, van de Donk NWCJ, Ramasamy K, Gamberi B, Streetly M, Offidani M, Bridoux F, de la Rubia J, Mateos MV, Ardizzoia A, Kueenburg E, Collins S, Di Micco A, Rosettani B, Li Y, Bacon P, Sonneveld P. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. J Clin Oncol. 2018 Jul 10;36(20):2035-2043. doi: 10.1200/JCO.2017.76.1742. Epub 2018 Feb 2. PubMed 29394124 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Jan 2017, 34 months.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 34 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2013
First posted
Jan 24, 2014
StartActual
Feb 28, 2014
Primary completionActual
Jan 27, 2017
CompletionActual
Jul 28, 2021
Last update
Aug 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02045017
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jan 24, 2014
Start date
Feb 28, 2014
Primary completion
Jan 27, 2017
Completion
Jul 28, 2021
Last update
Aug 27, 2021

Study contacts

Elisabeth Kueenburg, MD
study director · Celgene

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pomalidomide · Dexamethasone

Start the discussion